Seminars in Oncology
Volume 33, Issue 6 , Pages 688-695 , December 2006

Toxicity of Aromatase Inhibitors

  • Naimish Pandya
    • ,
  • Gloria J. Morris

      Affiliations

    • Corresponding Author InformationAddress correspondence to Gloria Morris, MD, PhD, Department of Medical Oncology, Thomas Jefferson University Hospital, 111 South 11th St, Suite G-4240, Philadelphia, PA 19107.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2006. CA Cancer J Clin. 2006;56:106–130
  2. National Cancer Institute: Cancer Surveillance Research. Fast Stats: Breast Cancer. Survival & Stage: Stage Distribution. Surveillance, Epidemiology, and End Results (SEER) program. http://seer.cancer.gov/faststats/
  3. Theobald AJ. Management of advanced breast cancer with endocrine therapy: the role of the primary healthcare team. Int J Clin Pract. 2000;54:665–669
  4. Buzdar AU, Robertson JFR, Eiermann W, et al. An overview of the pharmacology and pharmockinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer. 2002;95:2006–2016
  5. Buzdar AU, Douma J, Davidson N, et al. Phase III, multicenter, double-blind randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol. 2001;19:3357–3366
  6. Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol. 2000;18:3748–3757
  7. Mouridesen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol. 2001;19:2596–2606
  8. Nabholtz JM, Buzdar A, Pollak M, et al. Arimidex Study Group Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. J Clin Oncol. 2000;18:3758–3767
  9. Paridaens R, Therasse P, Dirix L, et al. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients—A randomized phase III trial of the EORTC Breast Group. 2004;2004 ASCO Annual Meeting Proceedings (post-meeting edition), 23, (abstr 515)
  10. Gradishar WJ. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women. Oncology. 2005;69:1–9
  11. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases. Lancet. 1896;2:104–107
  12. Carpenter R, Miller WR. Role of aromatase inhibitors in breast cancer. Br J Cancer. 2005;93(suppl 1):S1–S5
  13. Simpson ER, Davis SR. Minireview: Aromatase and the regulation of estrogen biosynthesis—Some new perspectives. Endocrinology. 2001;142:4589–4594
  14. Miller WR, Dixon JM. Local endocrine effects of aromatase inhibitors within the breast. J Steroid Biochem Mol Biol. 2001;79:93–102
  15. National Comprehensive Cancer Network. Breast Cancer: Clinical practice guidelines in oncology–v.1.200. 2005;http://www.nccn.org/physician_gls/f_guidelines.html
  16. Eisen A, Pritchard K, Johnston M, et al. Breast Cancer Disease Site Group The role of aromatase inhibitors in the treatment of postmenopausal women with metastatic breast cancer. Cancer Care Ontario. 2002;Practice Guideline Report No.1-5
  17. Blamey RW. Guidelines on endocrine therapy of breast cancer. Eur J Cancer. 2002;38:615–634
  18. Lester JE, Dodwell D, Horsman JM, et al. Current management of treatment-induced bone loss in women with breast cancer treated in the United Kingdom. Br J Cancer. 2006;94:30–35
  19. Lester J, Coleman R. Bone loss and aromatase inhibitors. Br J Cancer. 2005;93(suppl 1):S16–S22
  20. Shapiro C, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol. 2001;19:3306–3311
  21. Vehmanen L, Saarto T, Elomaa I, et al. Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients (The effect of clodronate treatment). Eur J Cancer. 2001;37:2373–2378
  22. Wheeler DL, Vander Greind RA, Wronski TJ, et al. The short and long-term effects of methotrexate on the rat skeleton. Bone. 1995;16:215–221
  23. Greep NC, Giuliano AE, Hansen NM, et al. The effects of adjuvant chemotherapy on bone density in postmenopausal women with early breast cancer. Am J Med. 2003;11:653–659
  24. Powles TJ, Hickish T, Kanis JA, et al. Effect of tamoxifen on bone mineral density measured by dual energy x-ray absorpimetry in health premenopausal and postmenopausal women. J Clin Oncol. 1996;14:78–84
  25. Leather AT, Studd JW, Watson NR, et al. The prevention of bone loss in young women treated with GnRH analogues with ‘add back’ estrogen therapy. Obstet Gynecol. 1993;81:104–107
  26. Hashimoto K, Nozaki M, Inoue Y, et al. The chronological change of vertebral bone loss following oophroectomy using dual energy x-ray absorptiometry: The correlation with specific markers of bone metabolism. Maturitas. 1995;22:185–192
  27. Eastell R, Hannon RA, Cuzick J, et al. Effect of anastrozole on bone density and bone turnover: results of the ‘Arimidex’ (anastrozole), Tamoxifen Alone or in Combination (ATAC) trial bone sub-protocol. 2002;24th Annual Meeting American Society for Bone and Mineral Research, San Antonio, TX, (abstr 1170)
  28. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793–1802
  29. Coombes RC, Hall E, Gibson LJ, et al. Intergroup Exemestane Study A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081–1092
  30. Lonning PE, Geisler J, Krag LE, et al. Effect of exemestane on bone: A randomized placebo controlled study in postmenopausal women with early breast cancer at low risk. J Clin Onco. 2004;22(14S):518;(abstr)
  31. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 1992;326:852–856
  32. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. J Clin Oncol. 2005;23:619–629
  33. Lonning PE, Jurgen G, Krag LE, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol. 2005;23:5126–5137
  34. Looker AC, Bauer DC, Chestnut CH, et al. Clinical use of biochemical markers of bone remodeling: Current status and future directions. Osteoporos Int. 2000;11:467–480
  35. Johannessen DC, Engan T, diSalle E, et al. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients (A phase I study). Clin Cancer Res. 1997;3:1101–1108
  36. ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365:60–62
  37. Eastell R, Hannon RA, Cuzick J, et al. Effect of anastrozole on bone density and bone turnover: Results of the ‘Arimidex’ (anastrozole), Tamoxifen Alone or in Combination (ATAC) trial bone sub-protocol. 2002;24th Annual Meeting American Society for Bone and Mineral Research, San Antonio, TX, (abstr 1170)
  38. Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian tamoxifen anastrozole trial. J Clin Oncol. 2005;23:5138–5147
  39. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97:1262–1271
  40. Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women completing ≥5 years of adjuvant tamoxifen: NCIC CTG MA.17b. 2004;27th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, (abstr 404)
  41. Goss P, Thompsen T, Banke-Bochita J. A randomized, placebo-controlled, explorative study to investigate the effect of low estrogen plasma levels on markers of bone turnover in healthy postmenopausal women during the 12-week treatment with exemestane or letrozole. Breast Cancer Res Treat. 2002;76:S76;(suppl 1, abstr 267)
  42. The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747–2757
  43. Brufsky A, Harker G, Beck T, et al. Z-FAST Study Group Zoledronic acid (ZA) for prevention of cancer treatment-induced bone loss (CTIBL) in postmenopausal women with early breast cancer receiving adjuvant Letrozole: Preliminary results of the Z-FAST trial. 2004;27th Annual San Antonio Breast Cancer Symposium, (abstr 1114)
  44. Brufsky A, Harker W, Beck J, et al. Z-FAST Study Group Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women with early breast cancer receiving adjuvant letrozole: 12 mos BMD results of the Z-FAST trial. 2005 ASCO Annual Meeting Proceedings J Clin Oncol. 2005;23:533;(suppl, abstr)
  45. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21:4042–4057
  46. Miller-Bass K, Newschaffer CJ, Klag MJ, et al. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med. 1994;154:2349–2355
  47. La Rosa JC. Triglycerides and coronary risk in women and the elderly. Arch Intern Med. 1997;157:961–968
  48. Danesh J, Collins R, Peto R. Lipoprotein (a) and coronary heart disease: Meta-analysis of prospective studies. Circulation. 2000;102:1082–1085
  49. deAloysio D, Gambacciani M, Meschia M, et al. The Icarus Study Group The effect of menopause on blood lipid and lipoprotein levels. Atherosclerosis. 1999;147:147–153
  50. Levi F, Randimbison L, Te VC, et al. Long-term mortality of women with a diagnosis of breast cancer. Oncology. 2002;63:266–269
  51. Bundred NJ. The effects of aromatase inhibitors on lipids and thrombosis. Br J Cancer. 2005;93(suppl 1):S23–S27
  52. Atalay G, Dirix L, Biganzoli L, et al. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: A companion study to EORTC trial 10951, ‘Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients. Ann Oncol. 2004;15:211–217
  53. Markopoulos C, Polychronis A, Zobolas V, et al. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: Preliminary results of the TEAM Greek sub-study. Breast Cancer Res Treat. 2005;93:61–66
  54. Hozumi Y, Saito T, Inoue K, et al. Effects of anastrozole on the lipid profile in postmenopausal breast cancer patients—A preliminary study. 2004;Fourth European Breast Cancer Conference, Hamburg, Germany, (abstr 300)
  55. Felson DT, Cummings SR. Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthritis Rheum. 2005;52:2594–2598
  56. Kidd BL, Photiou A, Inglis JJ. The role of inflammatory mediators on nociception and pain in arthritis. Novartis Found Symp. 2004;260:122–133
  57. Blomqvist A. Sex hormones and pain: A new role for brain aromatas?. J Comp Neurol. 2000;423:549–551
  58. Donnellan PP, Douglas SL, Cameron DA, et al. Aromatase inhibitors and arthralgia. J Clin Oncol. 2001;19:2767;(letter)
  59. Stoffel-Wagner B. Neurosteroid metabolism in the human brain. Eur J Endocrinol. 2001;145:669–679
  60. McEwen BS. Clinical review 108: The molecular and neuroanatomical basis for estrogen effects in the central nervous system. J Clin Endocrinol Metab. 1999;84:1790–1797
  61. Jenkins VA, Schiling V, Fallowfield LJ, et al. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? (A pilot study). Psychooncology. 2004;13:61–66
  62. Jones J, Vukelja S, Cantrell J, et al. A planned comparison of menopausal symptoms during year 1 in patients receiving either exemestane or tamoxifen in a double-blind adjuvant hormonal study. Breast Cancer Res Treat. 2003;82:S31
  63. Tralongo P, DiMari A, Ferrau F. Cognitive impairment, aromatase inhibitors and age. J Clin Oncol. 2005;23:4243

PII: S0093-7754(06)00322-8

doi: 10.1053/j.seminoncol.2006.08.011

Seminars in Oncology
Volume 33, Issue 6 , Pages 688-695 , December 2006

Article Tools

* Image Usage & Resolution